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WNT5A, a member of the WNT family of secreted proteins, activates the non-
canonical WNT pathway, regulates developmental events and is involved in tissue 
homeostasis. Misregulation of WNT5A has been associated with various types of cancer 
including pancreatic, colorectal, breast, lung and osteosarcoma. Recent studies have 
shown that WNT5A expression in cancer cells involves non-genetic (epigenetic) changes. 
The WNT5A gene has two similar transcription start sites (termed promoter A and 
promoter B in this study) and transcription from these sites give rise to two different 
messages that encode different protein isoforms. Epigenetic studies to date have focused 
on the WNT5A promoter A, however our preliminary analysis found that promoter B 
transcripts are nearly absent in osteosarcoma cells, but present in normal osteoblasts. The 
goal of this study was to determine if the decrease in promoter B transcripts in 
osteosarcoma was due to DNA methylation. We identified 6 CpG islands in the WNT5A 
intron 1 region which contains promoter B and exon 1B, and compared them with data 
available in NCBI epigenomics website. The NCBI database was also screened for data 
on the methylation status of these islands in various other cell lines and cancer types. The 
database analysis shows that there is little or no methylation of Regions 1 – 6 in cells, that 
normally express WNT5A (fibroblast, chondrocytes, and mesenchymal stem cells).  
However, in some colorectal tumor tissue there is extensive methylation within intron 1.  
In adjacent normal colon mucosa tissue, Regions 3 and 4 showed some degree of 
	
	
methylation. Methylation status of the CpG islands in normal osteoblasts and 
osteosarcoma (SaOS-2) was determined using Sodium bisulfite sequencing. The 
sequencing data showed that CpG Regions 1 and 2 are unmethylated. Regions 3, 4 and 5 
are completely methylated and Region 6 is partially methylated. In normal osteoblasts all 
6 regions were unmethylated. A demethylation experiment using 5-Aza-cytidine was 
performed to determine if decrease in methylation would increase promoter B transcripts.  
Treatment of SaOS-2 cells with 1µM 5-Aza-cytidine resulted in a 120 fold increase of 
promoter B transcripts. The methylation data of SaOS-2 cells treated with 1µM 5-Aza-
cytidine shows that CpG Region 6 is more prone to demethylation when compared to 
CpG islands 3, 4, 5. Two clones of Region 6 showed that 4 out of 5 CpG’s analyzed were 
demethylated. 5 clones of Region 3 and 4 showed that only 1-2 CpG’s were demethylated 
out of 24 CpG’s in Region 3 and 27 CpG’s in Region 4. Overall these results suggest that 
promoter B transcription is down regulated by DNA methylation of CpG Region 6 and 
Region 6 is more prone to demethylation compared to Regions 3. 4 and 5.
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CHAPTER I 
INTRODUCTION 
WNT5A Gene Structure  
The human WNT5A gene is located on chromosome 3, band p14.3, between 
55,499,744 and 55,521,331 base pairs (Entrez; Gene ID 7474).  Alternative splicing and 
different transcription start sites generate multiple transcripts from the WNT5A 
transcription unit. (Ensembl; Figure 1). In humans, 6 transcripts are generated leading to 
6 proteins. One transcription unit has 5 exons and 4 introns and produces an mRNA of 
6042 nucleotides (Ensembl; ENST00000264634, Figure 1).  The protein derived from 
this transcript has 380 amino acids. This transcript is derived from what will henceforth 
be referred to as promoter A and is the most well characterized of the WNT5A transcripts. 
Another transcript is derived from a promoter referred to as promoter B, located in intron 
1 of the promoter A transcript (Ensembl; ENSG00000114251, Figure 1). This transcript 
produces a 1299 bp transcript and a protein of 365 AA.  As such, the promoter B protein 
transcript lacks the first 15 amino acids of the promoter A protein.  This project is 
focused on the genomic sequences associated with the WNT5A promoter B. These two 
transcripts were chosen because WNT5A promoter A and promoter B proteins are the 
only WNT5A proteins present in mouse.  
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Figure 1. Human WNT5A Transcripts.  The two transcripts and associated promoters that 
will be studied are boxed. The ENST00000264634 transcript correlates with promoter A.  
The ENST00000497027 transcript correlates with promoter B. 
	
 
 
Figure 2. WNT5A transcripts 1A and 1B. Exon 1B is located in the intron of transcript 1a. 
Transcript 1a is derived from promoter A. Transcript B is derived from promoter B. 
 
Promoter A and promoter B give rise to distinct primary transcripts (Figure 2). 
cDNA clones have been isolated for promoter A (NM_003392) and promoter B 
(AK290869), which supports transcription from these alternate start sites. The intron-
exon structure of the promoter A and promoter B transcripts are compared in Figure 2. 
The promoter A transcript includes a unique exon 1A, whereas the promoter B transcript 
includes a unique exon 1B. Both transcripts share exons 2, 3, 4 and a portion of 5. The 
promoter B transcript has a much smaller 3’ untranslated region (UTR).  
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WNT Signaling and WNT5A 
WNT5A is an extracellular secreted glycoprotein and a member of the WNT 
family, which plays a role in development, proliferation, differentiation, movement and 
apoptosis (reviewed in Kikuchi et. al. 2012). WNT ligands are hydrophobic signal 
peptides that take part in cell signaling through the Frizzled transmembrane receptor 
proteins.  Wnt signaling acts through two pathways: canonical and non-canonical. The 
canonical (beta-catenin dependent) pathway is activated when the WNT ligand binds to 
the Frizzled receptor and the low-density lipoprotein related protein (LPR) co-receptor. 
This results in a hypophosphorylated beta-catenin, which is translocated into the nucleus. 
The nuclear beta-catenin binds to the lymphoid-enhancer-binding factor/T-cell-specific 
transcription factor (LEF/TCF) and activates target gene transcription (Vidal-Puig et al. 
2008; Nishita et al. 2010).   
The non-canonical (beta-catenin independent) pathways include the planar cell 
polarity (PCP)/ convergent extension (CE) pathway (PCP/CE pathway) and the Ca 2+ 
pathway (Imagawa et al. 2008), though the downstream signaling path way is yet to be 
fully understood. WNT5A signals through the non-canonical pathways by binding to the 
receptor kinase-like orphan receptor (Ror) 1/2 membrane receptor or different Frizzled 
receptors and activating RhoA and Rac, PCP/CE pathway and Ca 2+ pathway increasing 
calcium Ca 2+ ions, leading to effector protein kinase activation (Binder et al. 2007). The 
non-canonical pathway has been shown to have an antagonistic effect on the canonical 
pathway but recent studies have shown that WNT5A acts through canonical pathways as 
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well (Silver et al. 2009; Nishita et al. 2010). The consequence of WNT pathway 
activation/inhibition by WNT5A includes changes in cell migration, cell polarity, 
differentiation and proliferation (Kikuchi et. al. 2012). 
 
WNT5A, Development and Differentiation 
 WNT5A is involved in critical developmental events. When WNT5A was 
functionally deactivated in mice, their intestines were shortened and formed a bifurcated 
lumen instead of a single long tube and cell proliferation was also disrupted (Cervantes et 
al. 2009). In another study, an embryonic mouse knockout had truncated limbs and 
underdeveloped digits due to decreased proliferation of mesenchymal progenitor cells 
(Yamaguchi et al. 1999). Overexpression of WNT5A during early development was also 
shown to affect cell migration during avian gastrulation by disrupting the non-canonical 
Wnt signaling pathway (Hardy et al. 2008).  
WNT5A more recently has been found to be involved in brain development and 
nerve cell differentiation. A WNT5A knockout mouse displayed defects in midbrain 
morphogenesis such as a rounded ventral cavity and impaired elongation of the midbrain 
(Andersson et al. 2008). WNT5A expression affected D1x homeogene expression, which 
promotes differentiation of interneoruons (Paina et al. 2011). And, in another study of 
WNT5A knockout mice, the density of dopaminergic neurite and axon outgrowth was 
disrupted (Blakely et al. 2011).  
	
	
5
Most relevant to this study, WNT5A was found to be a regulator of mesenchymal 
stem cell differentiation into osteoblasts, preadipocytes or myoblasts (Vidal-Puig et al. 
2008). In a more recent study, the absence of WNT5A stopped ontogenesis from human 
mesenchymal stem cells, whereas its presence inhibits the formation of preadipocytes 
from human mesenchymal stem cells (Bilkovski et al. 2010). Expression of WNT5A was 
also shown to be necessary for osteoblast and chondrocyte differentiation in mouse 
endochronal skeletal morphogenesis (Wu et al. 2003). WNT5A was found to coordinate 
proliferation and differentiation of chondrocytes by regulating cyclin D1 and p130 
expression (Yang et al. 2003). 
 
WNT5A and Cancer 
WNT5A expression is altered in various types of cancers including osteosarcoma, 
lung, thyroid, leukemia, colorectal and skin (reviewed in Katoh and Katoh, 2009).  
WNT5A appears to function as both an oncogene and tumor suppressor gene. In several 
cancers, such as colon and breast cancer, WNT5A is downregulated (Ying et al., 2008; 
Leris et al., 2005), suggesting it acts as a tumor suppressor, conversely, it was found to be 
overexpressed in some gastric and pancreatic cancers (Kurayoshi et al., 2006: Ripka et 
al., 2007), suggesting it was acting acting as an oncogene. Weeraratna et al. (2002) 
examined the role of WNT5A in melanoma metastasis by transfecting WNT5A expression 
vectors into melanoma cells.  These WNT5A overexpressing cells showed an increase in 
protein kinase C (PKC) activity, a protein that plays a role in cell motility and 
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cytoskeleton changes. In that study, Frizzled-5/WNT5A interaction was also disrupted by 
using an antibody against Frizzled-5. The cells treated with the antibody showed 
decreased motility in the Boyden chamber invasion assay and the cell movement scratch 
assay. A decrease in PKC activity was also detected. Overexpression of WNT5A has also 
been shown to play a role in metastasis in pancreatic cancer (Ripka et al., 2007).  These 
studies show a strong association between cell movement and increased WNT5A 
expression during metastases.  
 
WNT5A and Osteosarcoma  
 WNT5A plays a critical role in the development of osteoblasts and osteoclasts. In 
one study, formation of osteoclasts and osteoblasts (osteoclastogenesis) was enhanced by 
WNT5A binding to the Ror 1/2 and activation of a non-canonical WNT signaling 
pathway. This study also showed that osteoblasts cells express WNT5A and that its 
deficiency leads to impaired osteoclastogenesis (Maeda et al. 2012). Another study also 
revealed that overexpression of WNT5A enhanced osteoclast differentiation and the non-
canonical WNT5A signaling accelerates loss of bone mineral density in HIV infected 
individuals (Santiago et al. 2012). 
 Since these studies have shown the importance of the WNT5A signaling pathway 
in osteoclastogenesis, it would be expected that WNT5A has a role in osteosarcoma. 
Osteosarcoma is a malignant bone tumor, which usually develops during a period of rapid 
growth that occurs in adolescence. It occurs most commonly in larger bones and in areas 
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of bone with the fastest growth rate. In one study, the WNT5A signaling in osteosarcoma 
cells was shown to give these cells some of their metastatic invasive properties (Enomoto 
et al. 2009). In agreement, high levels of the WNT5A were detected in patients with 
severe osteosarcoma and thus might have a role in its occurrence and progression (Lu et 
al. 2012).  Nakano et al. (2003) did a microarray study in which they compared the 
expression of 637 cancer-related genes to detect differential expression between high and 
low metastatic sublines of osteosarcoma. They found that WNT5A was one of the genes 
associated with adherence, invasiveness and motility of these cells. In a study conducted 
by Ren et al. (2011), they showed that suppression of WNT5A expression leads to 
inhibition of in vitro cell motility and invasiveness. Thus, WNT5A plays an important role 
in the occurrence and metastasis of osteosarcoma. 
 
DNA Methylation 
A single human cell contains a full complement of genetic information but 
depending on the function of the cell not all genes are expressed.  Gene expression and 
regulation play a crucial role in controlling cell type, cellular functions, development, cell 
cycle, and tissue homeostasis. Epigenetics is the study of heritable changes in gene 
regulation and expression without changing the underlying genetic sequence. One   
epigenetic mechanism is DNA methylation. 
DNA methylation is the addition of a methyl group on the position 5 carbon of 
cytosine. This methylation occurs in CpG dinucleotides (Cytosine-phosphodiester bond-
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Guanine) and the methyl groups lie in the major groove of the DNA. When both strands 
of the DNA are symmetrically methylated they are near each other in the same direction. 
CpG dinucleotides are usually grouped together in CpG islands. CpG islands are regions 
around 200 base pair long with a GC content of more than 50%.  
DNA methyl transferases (DNMT’s) are enzymes responsible for the addition of 
the methyl groups. There are three types; DNMT1, DNMT3a and DNMT3b. DNMT1 is 
responsible for the methylation of hemimethylated DNA. When DNA undergoes 
replication the parental strand retains the methyl groups and DNMT1 is responsible for 
matching those methyl groups on the newly synthesized daughter strands. DNMT3a and 
DNMT3b are responsible for de novo methylation of DNA during early development.  
The addition of the methyl groups can cause transcriptional repression by either 
inhibiting proteins from binding to the DNA or serving as a site for binding of proteins 
with repressive functions. There are families of proteins that recognize methylated DNA 
(reviewed in Prokhortchouk et al. 2008). One family of proteins has a related methyl 
binding domain (MBD) and includes MBD1, MBD2, MBD4 and MeCP2 proteins.  The 
second family includes zinc finger proteins that bind to the methylated DNA and contains 
the proteins Kaiso, ZBTB4 and ZBTB38, all of which affect transcription. A third family 
of related proteins includes UHRF1 and UHRF2, which may have a role in methylation 
dependent transcriptional regulation (Prokhortchouk et al. 2008). 
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WNT5A Epigenetic Alterations 
 
Recent studies have shown that WNT5A misregulation in cancer cells involves 
non-genetic (epigenetic) changes rather than genetic ones, such as gene mutation and 
structural rearrangements. DNA hyper or hypomethylation of the WNT5A gene regulatory 
region have been detected in various cancers. 
 The promoter region of WNT5A was found to be hypermethylated and 
epigenetically silenced or down regulated in esophageal squamous cell carcinoma 
(ESCC) and treatment with 5-Aza-cytidine, a demethylating agent, resulted in WNT5A 
reexpression and demethylation of its promoter in silenced cell lines (Li et al., 2010). 
Also, ectopic expression of WNT5A inhibited proliferation and motility of the ESCC 
cells. Ying et al. (2008) studied WNT5A methylation and determined that the promoter 
region is hypermethylated in colorectal cancer and demethylation of this region resulted 
in reactivation of WNT5A expression. Similarly, hypermethylation of the WNT5A gene 
was detected in patient tissues with colorectal cancer, whereas no methylation was 
detected in the normal tissues from the same patients (Hibi et al. 2009).  
 Decrease in WNT5A mRNA levels was associated with WNT5A hypermethylation 
in acute lymphoblastic leukemia patient derived cell lines. WNT5A expression was 
restored after being treated with 5-Aza-cytidine (Roman-Gomez et al., 2007). In another 
study, the methylation status of WNT5A promoter- exon 1 was analyzed and it was 
observed that there is hypermethylation of the promoter region in acute myeloid leukemia 
(Martin et al., 2009). Conversely, in a study by Wang et al. (2007), three CpG sites in the 
	
	
10
5’ untranslated region (UTR) of WNT5A were consistently methylated in normal prostate 
cells but were hypomethylated in prostate cancer cell lines. These studies support the 
conclusion that altered DNA methylation of the WNT5A promoter genomic region is 
associated with WNT5A misregulation in cancer. Currently, nothing is published on 
WNT5A promoter B associated CpG island methylation. 
 
WNT5A Promoter A and B Regulation 
 Previous research in this lab focused in transcriptional regulation from the distinct 
WNT5A alternative promoters A and B. Results from these studies formed the basis of 
this project. The individual promoter regions A and B were cloned into luciferase transfer 
vectors and deletion constructs were generated. These were used to analyze expression in 
different cell types and to identify specific gene regulatory regions. Results showed that 
promoters A and B were both active in Caco-2 (epithelial) and NIH 3T3 (fibroblast) cells 
and that 300-450 bp of upstream sequence are sufficient for maximal expression (Katula 
et. al. 2012). Significantly, promoter B constructs displayed distinct patterns of 
expression in two cell types and were more responsive to tumor necrosis factor (TNF)- 
alpha (Katula et. al. 2012). These results indicated that WNT5A promoters A and B are 
differentially regulated. 
 Taqman primer/ probes were designed to detect promoter A and B transcripts by 
qRT-PCR (Hsu 2011, Katula et. al. 2012). These primer/ probes were initially used to 
determine if endogenous promoter A and promoter B transcript levels varied during 
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differentiation and cancer progression. Promoter A and B transcript levels were 
quantified during differentiation of mouse fibroblast cells 3T3-L1 into adipocytes. 
Results showed that the ratio of A to B varied and promoter B transcript levels were the 
highest in undifferentiated 3T3-L1 cells. B transcripts decreased in adipocytes (Hsu 
2011).   
Promoter A and B transcripts were quantified in normal human osteoblasts and 
osteosarcoma cell line SaOS-2. Promoter B transcripts were nearly undetectable in the 
SaOS-2 cells. In normal osteoblasts, B transcripts were nearly 10 fold higher than A 
transcripts and approximately 450 fold higher than B transcripts in osteosarcoma cells. 
Promoter A transcripts were detected in both osteoblast and osteosarcoma cells but there 
were approximately 3.5X promoter B than A transcripts in the osteosarcoma cells. These 
data indicate that transcription from promoter B is greatly reduced during progression of 
osteoblasts to osteosarcoma. Promoter B reporter constructs were transfected into 
osteosarcoma SaOS-2 cells. All constructs were expressed at a relatively high level (Hsu 
2011). This result indicates that the decrease in promoter B transcript levels in 
osteosarcoma is not due to altered transcription factors. The other likely possibility is that 
promoter B associated CpG islands become methylated, reducing transcription of 
promoter B.
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CHAPTER II 
MATERIALS AND METHODS 
Bioinformatics Search 
The NCBI epigenomics search tool (http://www.ncbi.nlm.nih.gov/epigenomics) 
was used to find WNT5A relevant data. This site contains experimental data from various 
epigenetic studies on many human cell types. I focused on the studies of DNA 
methylation data that were available for mesenchymal cell types including mesenchymal 
stem cells, chondrocytes, fibroblasts, and osteoblasts in the WNT5A genomic region. I 
focused on the DNA methylation status of the 6076 bp of intron 1, which includes 
promoter B, exon 1B and upstream sequences in the WNT5A gene (Fig. 2). I also looked 
at the CpG islands that were documented in these experiments. I compared the DNA 
methylation status of the mesenchymal stem cells, chondrocytes, and fibroblasts with 
each other and in relation to our identified CpG islands. 
 The database was also searched for the DNA methylation data of different 
samples of colorectal cancer and the DNA methylation status of the WNT5A intron 1 
region compared. The DNA methylation status in relation to the identified CpG islands 
and the methylation status of each colorectal cancer to its normal colon mucosa cells, 
with respect to the CpG islands were compared. Some of the more relevant cell types 
were not available, e.g. osteoblasts 
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Identification of CpG Islands 
 The CpG islands were identified using an online program called “CpG 
Embossplot”. The program searched the 6076 bp long WNT5A intron 1 sequence for 
putative CpG islands. The parameters for the search were that the regions should be more 
than 200 base pairs long. The GC percentage should be greater than 50% and an 
observed-to-expected CpG ratio greater than 60%.  
 
Primer Design 
 The primers were designed using an online program called “Methprimer”. The 
sequence of each CpG island along with 100-200 bp upstream and downstream sequences 
was entered into the program. Then the program used product size, melting temperature 
and primer size as parameters to generate the primers. 
  
Cell Culture 
 SaOS-2 osteosarcoma cells were obtained from the American Type Culture 
Collection (ATCC, CAT # HTB-85). The cells were grown in McCoy’s 5a Modified 
medium containing 15% fetal bovine serum and penicillin/streptomycin (50 I.U./ 50 µg 
per ml). The cells were grown at 37°C, 5% CO2 humidified cell culture incubator.  
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Isolation of Genomic DNA 
  SaOS-2 cells were plated at 1x105 cell in 100mm plates and grown for 2-3 days. 
The cells were collected by trypsinization. The cells were pelleted by centrifugation (5 
mins at setting #3 on a clinical centrifuge) and resuspended in 1X Phosphate Buffered 
Saline (PBS). The cells were counted using a hemocytometer and aliquots representing 
1x106 cells were transferred to a microfuge tube and pelleted by centrifugation. Genomic 
DNA was isolated from the cell pellets using a Genomic DNA Isolation Kit (Zymo 
research, D3004). The cells were lysed using 200 µl of Genomic Lysis Buffer, then 10 µl 
ZymoBeads was added to this and incubated at room temperature for 5 minutes. The 
mixture was centrifuged and the pellet was collected and washed twice with 200 µl of 
DNA Wash Buffer. The DNA was eluted using 35 µl  Elution Buffer. The DNA 
concentration and purity was determined by reading the optical density at 260 and 280 
nm. Osteoblast genomic DNA was purchased (ScienCell, #4609). 
 
DNA Bisulfite Conversion 
The genomic DNA was bisulfite converted using the EZ DNA Methylation Kit 
(Zymo research, D5001).  500-550 µg of genomic DNA was mixed with 5 µl of M-
Dilution Buffer and water in a 50 µl reaction and incubated at 37°C for 15 minutes and 
100 µl C-T Conversion Reagent was added. The mix was incubated at 50°C for 12-16 
hours then put on ice for 10 minutes. The reaction was mixed with 400 µl of M-Binding 
Buffer and spun through a Zymo-Spin™ IC Column. The column was washed with 100 
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µl of M-Wash Buffer and 200 µl of Desulphonation Buffer was added to remove the 
bisulfite from the reaction. The converted DNA was eluted using 10 µl of Elution Buffer. 
The final DNA concentration was determined by reading its optical density at 260 and 
280 nm.  
 
PCR Amplification and Subcloning  
Bisulfite specific primer sets for PCR amplification of CpG island regions from 
converted DNA were designed using an online tool called Methprimer 
(http://www.urogene.org/methprimer/). These primers are listed in Table 2. The sequence 
of each CpG island along with 100-200 bp of upstream and downstream sequence was 
entered into the program. The program then uses primer size and primer melting 
temperature to generate forward and reverse primers. These primers are complimentary to 
sequences flanking the CpG islands but lack any CpG’s.  
1-2 µl of the bisulfite converted DNA with concentration 15- 30 ng/µl was 
typically used for PCR amplification using the generated bisulfite specific primers. The 
amplification was done using using ZymoTaq DNA polymerase (Zymoresearch, E2001) 
and the amplification condition was determined using melting temperatures of respective 
primers for each region. The PCR product was verified by running 10µl of the products 
on a 2% agarose gel along with a 100 bp DNA marker and visualized with UV 
transillumination. 
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The verified PCR product (40 µl) was run on a 1.5% low melt agarose gel. The 
bands at the correct sizes were excised and purified using the QIAquick Gel Extraction 
Kit (Qiagen, 28704). The gel piece was mixed with 3X gel volume of QG buffer and 
incubated at 50°C for 10 minutes. Gel volume of Isopropanol was added to the mix and 
spun in QIAquick Spin Columns. The column was washed using 750 µl PE Buffer and 
eluted using 30µl Elution Buffer. The concentration of the purified PCR product was 
determined by reading the optical density at 260 and 280 nm. Then, purified PCR product 
2-4 µl with concentration 10-50 ng/µl was cloned into TOPO vector using the TOPO 
cloning kit (Invitrogen, 450641) and incubated at room temperature for 10 minutes. 2 µl 
of the “vector – PCR mix’ was transformed into competent DH5α E. coli (50 µl). The 
mixture plus cells were incubated on ice for 10-20 mins and then heat shocked at 42°C 
for 30 seconds and placed on ice for 5 mins. The transformed E. coli was shaken 
horizontally for 1 hour at 37°C. 250 µl S.O.C growth medium (Invitrogen,15544-034) 
was added to the cells. 150 µl of the transformation growth media mix was plated on 
Luria Broth (LB) -Ampicillin (AMP) plates coated with 40 µl of  5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-Gal) (40 mg/ml) and grown overnight at 37ºC. The 
white colonies were picked and plated on a LB-AMP masterplate and grown overnight in 
LB-broth with 100 µg/ml ampicillin at 37ºC.  
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Plasmid Screening, Purification and Sequencing 
The plasmids in the minipreps of white colonies were screened for inserts. The 
individual bacterial colonies grown overnight in LB-AMP broth were pelleted by 
centrifugation. The supernatant was removed and the cells were resuspended and lysed 
using 200 µl of Lysis Buffer (Lysozyme [Sigma-Aldrich, L7651],  0.15 mg, 8% Sucrose, 
0.5 % Triton X-100, 50mM EDTA, 10 mM Tris-HCl, pH 8.0). The mix was boiled for 40 
seconds, placed on ice for 10 minutes and centrifuged for 6 minutes at top speed. 10 µl of 
the supernatant mixed with sample buffer was run on a 1.5% Agarose gel with a Lambda/ 
Hind III marker. The gel was visualized with UV illumination and plasmids with inserts 
were picked. 
Plasmids with verified inserts were grown overnight at 37°C and was purified 
from bacterial clones using the Promega Plasmid Miniprep Kit (Promega, A1460). The 
bacterial cells were pelleted by centrifugation and the supernatant was aspirated. The 
cells were resuspended in 200 µl Resuspension Buffer and 200 µl Cell Lysis Buffer was 
used to lyse the cells. 200 µl of Neutralization Buffer was added and the mix was 
centrifuged for 6 mins. The supernatant was collected and mixed with Wizard Miniprep 
DNA Purification Resin and run through a Wizard Miniprep Column. The column was 
washed with 2 mL Column Wash Buffer and dried. The plasmid was eluted using 30-50 
µl of nuclease free water. The insert size was verified by using 500-550 ng of the plasmid 
and conducting a restriction digest using EcoRI (Promega, R6011). The restriction 
digestion reaction was run on a 1.5% Agarose gel and visualized using UV 
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transillumination and inserts were verified by band size. Verified plasmids were sent to 
Eurofin MWG Operon facility for sequencing. 
 
DNA Sequence Analysis 
 Sequencing results were available from Eurofin. Each sequence was provided in 
different formats. Using MacVector format, the sequence was compared to a generated 
bisulfite converted sequence of that same region, which was assumed to be methylated. 
Hence, all the C’s in the CpG’s remained a C. all other C’s were converted to T’s. The 
obtained sequence was aligned to the bisulfite converted sequence using the MacVector 
alignment tool. Each CpG was visually examined. A methylated CpG in the experimental 
sequence would be aligned to the bisulfite converted CpG. An unmethylated CpG would 
be converted to a T and not aligned to the converted sequence 
 
5-Aza-cytidine Treatment of Cells 
5-Aza-cytidine was made by adding 200 µl of 1:1 solution of Glacial Acetic Acid 
and Nanopure water into the 100 mg 5-Aza-cytidine stock. 10 µl of the 5-Aza-cytidine 
stock solution was added to 90 µl of 1:1 of Glacial Acetic Acid and Nanopure water 
solution to make a 1:10 dilution.  
The SaOS-2 cells were plated in 100 mm plates at a density of per 100 mm plates 
and grown overnight.  The cells were treated with 0, 1, 5 and 10 µM 5-Aza-cytidine 
(InvivoGen, met-adc-1) on day 1 and 3. The 1, 5 and 10 µM 5-Aza-cytidine final 
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concentrations were made according to Table 3. The On day 4, the cells were collected 
and stored at -80ºC. RNA and DNA was isolated from the cells.  
 
Table 1. Preparation of 1 , 5 and 10 µM 5-Aza-cytidine final concentrations 
Final 5-Aza-cytidine 
concentration 
5-Aza-cytidine 1:10 
dilution 
1:1 Glacial Acetic Acid and 
Nanopure water 
0 µM 0 µl 5 µl 
1 µM 0.45 µl 4.05 µl 
5 µM 2.25 µl 2.25 µl 
10 µM 4.5µl 0 µl 
 
RNA Isolation, cDNA Preparation and qRT-PCR  
First, the medium was removed from the cells and the cells were washed with 
cold, sterile 1X PBS. 5 mL 1xPBS was added and the cells were scrapped from plate and 
transferred to a 15 mL Faclon Tube. The cells were centrifuged for 5 minutes at setting 
#4 in a clinical centrifuge.  The PBS was removed and the cells were quickly resuspended 
in 175µl RNA Lysis Buffer. RNA was isolated using the Promega SV Total RNA 
Isolation Kit (Promega, Z3100). 350 µl of RNA Dilution Buffer was added and mixed.  
The sample was heated at 70°C for 3 minutes and the cleared lysate was removed to a 
clean tube and 200µl of 95% ethanol was added. The mixture was spun through a RNA 
Isolation Column for 1 minute in a microfuge. The column was washed with 600µl of 
RNA Wash Solution and incubated for 15 mins at room temperature. 50ul of DNAse mix 
was added to the top of the resin and was incubated for 15-20 mins at 20-25°C and the 
reaction was stopped with 200µl of DNAse stop solution. The columns were washed 
again with RNA Wash Solution and the RNA was eluted with 100µl of Nuclease free 
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water. The quantity and the purity of the RNA was determined by reading at 260 and 280 
nm. 
The isolated RNA was converted into cDNA using the Maxima First Strand 
cDNA Synthesis Kit (Maxima, K1641). The 1-5 µg of RNA was used to make a 20 µl 
master mix containing 1x Reaction Mix, Maxima Enzyme Mix and Nuclease Free Water. 
The reaction mix was incubated at 25°C for 10 minutes and 50°C for 15 minutes. The 
reaction was terminated by incubating the mix at 85°C for 5 minutes. The resulting 
cDNA strand was used to perform a qRT-PCR reaction to quantify promoter A and 
promoter B specific transcripts. A total assay set required 48 samples. This included three 
replicas of each target transcript (promoter A, promoter B and GAPDH as an internal 
control) for each sample cDNA (0, 1, 5, 10 µM 5-Aza-cytidine). In addition, promoter A 
and B PCR standard curves were included for quantification of transcript numbers. 
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CHAPTER III 
RESULTS 
Identification of CpG Islands 
 The WNT5A promoter B start of transcription and exon 1B are located in intron 1 
of the promoter A transcription unit (see Fig. 2). As such, we wanted to identify CpG 
islands within the intron 1 sequences. These sites are likely to influence promoter B 
transcription. Initially, intron 1 was analyzed using “Emboss CpG plot” (see Materials 
and Methods). Five CpG island regions were identified. Then, the CpG islands included 
in these same sequences that were identified by the University of California Santa Cruz 
(UCSC) Genome Browser were considered giving a total of six islands. Table 2 includes 
the base pair size and number of CpG’s for each region. The DNA sequence and location 
of each CpG for each region is shown in Figure 3. 
 
Table 2. WNT5A Intron 1 CpG Island Characteristics 
Region	 Size	(base	pairs)	 Number	of	CpG’s	
Region‐1	 343	 27	
Region	‐2	 617	 39	
Region	‐3	 441	 24	
Region	‐4	 350	 27	
Region	‐5	 578	 25	
Region	‐6	 385	 26	
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REGION 1 
                                     1        2 3     4    5         6         
CAGGATAATGATTCAATTCAACAAATATTTACCAAGCGCCCACTGCGCGGGCACCGGGACGGTGTGTGGCCGGGGCT 
 7                                   8                              9  10 
CGGGATGGGGAAAGGGACTCCTTGGTTGAGAGAACCCGCAGAGGAACTAGGGGCCAACTACTCCAGAGCGGCGTACA  
       11         12   13 14                           15       16  17 
CCTTCCCCGACACCCCCCCGCACCGACGGAGGCCAGATTGTAGGCTTGCCTTGGCCGAGTAACTCGAGCGCTTCAGG 
                         18         1920     21 2223     24   2526   
CCCCTTTGCCTTTAAGAGTGCCTGGCGGGGGGCCAGCGCGCACCCCGGCGCGGGGAGCGGGGTCGCGTTATTAGCAT 
       27 
TATTAGCCGCCACTGGGTGAGCTCAGGCACTTTGC 
REGION 2                                                                        
                                1           2        3    4     5 6    7 
TAGTTTCTAGACAGACTCTGCCAGGGGAGTTTCGAGGGGGCAATGCGGAGAGTGCGCAGCGAACCGCGGGCCGACAA 
            8                     9         10                             11 
ATGTGTGTGTGTCCGAGTGTGTGGATCCTTGGCTGCGTGTGTGTGCGTGTGTGTTTGTGTGTGTAGGGGAGTTGTTC 
            12                                      13  14   15          
TCGGGTCCAGGACGTAGTAGCCTAGAGTCCCCTGTCTTCTCCTCCCCTCCCCCGTGCGCTCCGGTGCTCAAGGGGTT 
         16 17      18          1920             21 22  23    24 
AGCACTATGCGCGCAGAACTCGGAGCCATCCCCGCGGCCTTTTCTTCCCCGCGGTGCGGTGCCGGCTGCCCCCTGTT 
   25                  26     27           28  29  30      
GGCCGCCTTGAGGTAGGACTCCTGCGAGCCTCGGTTCCTTGGGGCGGGCGGGCGGGCAGCTGCTCCCCTCTCCCTCC 
                        31                                 32    
CACCCCTGCTCCCTTCATCCCTCCCGACCACCAGACCCCACTCTCCCAGCAGGGGCCCTCGGAGGCCCCCAGAGGAC 
      33   34 35 36  37        38          39       
CAGTTTCGCTGCGCCGCCGGCCGCTGCAATACGGAAGGGGCCACGGGTCCAGCCCAGCAAATGGGACTCGGCCAGCT 
REGION 3                                                 
                                                   1                    2 
GGGAGAGGATCTTTGCTTGGCCTTTTTATCTATTCTCTTAAGGGACTGCTGCGGAGGAGGAGTTGGGTGTTGCGAGA 
                3          4 5      6   7 
CTTTAGGTGTGCATCCGGCTGCTCCCCGCGCCCTCCGAACGTCCTCTGAACAATTTTGCTACTGAGGTTTCCTCTCT 
                8        9    10                                   11 1213 
CCCTCATCCCTCATCACGCCTGGCCCGCACCGTGGTTGGTAAAGAAGGATCAAGAACACCTTTAATCCGACGCGAAG 
                             14 15                            1617    18 
GCTTTGAGGGATACATAGAAAGGGAGCCACGTCGTTGAGCTGCTCTGGATTGAAGAGGAGGACGCGGGAACGCCCTC 
                     19              20                 21     2223 
CTCCACCTCACTCCTCTGGTGCGCTGAGCCCCTCAAACGCCCCCAGTCCTCCTCCCCGTGGCACGCGAGGAAGATTC 
                                                                        24 
TCAGTGTCCTTACAGAGTCATCTTCCCCTGAAGATTCTCAGTGTCCTTACAGAGTCATCTTCCCCTGAGCCCCGAAA 
 
GTGTTGGAAAACATTTAGCCCC 
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Figure 3. A-F, Sequence of WNT5A intron 1 CpG islands. Each CpG is highlighted in red 
and numbered. 
 
REGION 4 
                                1         2 
CCTGGAGCCAGGGAGACCCAAGTCTTGGTGACCGGATGGGCCCGCTCTCAGTTGGCCTGGGCTCTGGGAACTGGTGG 
                  3                4              5                  6         
ACTCTCCCTGGGGGCTTCGGGCTGGGAGTGGGTTCGGTTTGTGTGGCTTCGGCTCTAACAAAGAGATCCGCTGAATC 
  7  8                                9      1011   12  13 1415                
CGCCGAATCTGTTATCAATTTCTCTGCTGCTTGAGCCCCGCCCCACGCGCCCCGCTCGCCGCGAAGCTTGGAAAGTG 
  1617                  18      19         20   21              2223 
CACGCGGCCAGCACCAATCTGGGCCGCTGACTCGGAAACATGTCGCAGCGTGTGTGTCTATGCACGCGTGTGAGTGT 
           24                           2526    27 
GTAAATGTGCACGAGTGTGAATGTGTATGATGTGTGTGCACGCGGCATCGGCTGCCCTTGGGGAGAGTTGACTTTGC 
 
AGCCTGGGCTG 
REGION 5 
                               1                             2 
AGGGCTGCCTAGGTCCCCTCTGCCCCTTTTACGGCACAGGTTCCAAGCCAGGCTCTTCCACCGCCTTAAAGAGGCTC 
                                                 3         4              5 
ACCTTTCTTTTCTTTTCTGTGGAAGGGGCTCCTTCAGGGGCTATGGGCGATGCAGTGCGGCAGGGTTAGACTTACGT 
                    6          7       8          9    10 11 12 
GTAAGGGGATTTTTAAAACCCGCTCCTCCCACCCGCACCCGCCACCTACTCGCTCCGCCGCCGCCTACAGGTGGAGA 
                   13    14 
AGTCACCAGTGGGGAGGAACGGCAGCGGAAGCTTCCAAGGCCAACTCCTACCCCTGAAATTCTTCAGGAAGGGAACC 
  15 16                        17   18        19   20        21          22 
TTCGCCGCTGGGGGCCTCTTTGCCCTGGAATCGATGCGCCCAGCTGCGGCTCGGAAGCCAGCGCCTCTGGCCCCGTC 
                           23   24             25         
TGGACTCATCTGCAAGGGCTCTGGCCTCGCCCCGCACCCCCACCTTTCGGCACTGAC 
RRGION 6 
                       1               2   
CCCTCCCTAGTCTGGCTGAAGAACGTCCTTAAGGAAATCCGGGCTGCTCTTCCCCATCTGGAAGTGGCTTTCCCCAC 
  3    4                     5          6                            7 8 9 
ATCGGCTCGTAAACTGATTATGAAACATACGATGTTAATTCGGAGCTGCATTTCCCAGCTGGGCACTCTCGCGCGCT 
      10      11                         1213                       1415 
GGTCCCCGGGGCCTCGCCCCCCACCCCCTGCCCTTCCCTCCCGCGTCCTGCCCCCATCCTCCACCCCCCGCGCTGGC 
     16                   17    1819       20    21         22  
CACCCCGCCTCCTTGGCAGCCTCTGGCGGCAGCGCGCTCCACTCGCCTCCGTGCTCCTCTCGCCCATGGAATTAATT 
                  23                   24         25   26 
CTGGCTCCACTTGTTGCTCGGCCCAGGTTGGGGAGAGGACGGAGGGTGGCCGCAGCGGGTTCCTGAGTGAATTACCC 
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These CpG islands were the focus of the DNA methylation analysis in this study. 
More recently, our CpG islands were compared to the UCSC Genome Browser CpG 
island map and the NCBI for the WNT5A intron 1 (Fig. 4). 
 
 
 
Figure 4. Comparative location and size of the selected CpG islands. CpG islands found 
in this proposal are compared with the UCSC Genome Browser CpG island map and the 
NCBI Epigenomic Browser CpG Island map. 
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Bioinformatics Analysis of the WNT5A Intron 1 Sequences 
 
  Numerous genomic scale epigenetic analyses have been completed and the 
resulting DNA methylation data deposited into searchable databases. The NCBI 
epigenome database was searched to generate an “epigenetic portrait” of the WNT5A 
intron 1 region. I chose to look at data that were related to WNT5A normal expression and 
some cancers having misregulated WNT5A or WNT signalling. WNT5A is primarily 
expressed in mesenchymal cells, hence experiments including chondrocytes, fibroblasts, 
adipocytes, osteoblasts and mesenchymal stem cells were searched. 
 DNA methylation data from two different donor samples of mesenchymal stem 
cells derived from the bone marrow showed that there is very little methylation in each of 
the six CpG islands. Similarly, two different human fibroblast cell lines (Fib 20 and Fib 
17), derived from the H9 human embryonic stem cell line had little methylation in the six 
intron 1 CpG islands (Fig. 5). And, data from three different donor samples of 
chondrocytes derived from the bone marrow also showed very little methylation (Fig. 5). 
These results suggest that the WNT5A intron 1 region is not methylated or has very little 
methylation in cells in which WNT5A is normally expressed. Unfortunately, DNA 
methylation data was not available for all cell types of interest. For example, while 
epigenetic experiments were completed with osteoblasts there were no DNA methylation 
data. There were no DNA methylation data for osteosarcoma cells. 
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Figure 5. WNT5A intron 1 DNA methylation profiles. Methylation profiles from different 
samples of Fibroblast, Chondrocytes and Mesenchymal Stem Cells. The WNT5A intron 
region is shown above. Vertical lines indicate that some DNA methylation was detected 
at that position.  
 
WNT5A expression is also associated with colorectal cancer (King et al.2008, 
Hibi et al.2009, Rawson et al. 2011)  The NCBI epigenomic database contains DNA 
methylation data from five different colon cancer samples with their respective normal 
cells from the colon mucosa (Fig. 6). The colon cancer sample from a 31 year old patient 
shows a higher level of methylation in the CpG island Regions 3 and 4 when compared to 
methylation data from its normal colon mucosa tissue. Another sample from an 81 year 
old colon cancer patient showed an increase in the level of methylation in all six CpG 
islands . Other colon cancer samples from patients aged 67, 70 and 85 did not show much 
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difference in methylation between the cancer and corresponding normal tissue. When 
compared to the DNA methylation data for human mammary epithelial cells, normal 
colon mucosa cells had a higher level of methylation in CpG island Regions 3 and 4 (data 
not shown). These data suggest that in normal colon epithelial cells, CpG island Regions 
3 and 4 are more susceptible to DNA methylation. In transformed colon epithelial cells, 
the amount and regions of DNA methylation generally increases. 
 
 
Figure 6. WNT5A intron 1 DNA methylation profiles from different Colorectal Cancer 
patients compared to Normal Colon in the patients. The WNT5A intron 1 region is shown 
above. The black areas indicate relative levels of DNA methylation at that particular 
sequence. Note that the scales vary. 
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DNA Methylation Analysis of WNT5A Intron 1 CpG Islands 
 
The methylation status of the six CpG islands was analyzed by bisulfite 
sequencing. The sodium bisulfite specific primers designed to amplify each CpG island 
with their respective amplification condition are shown in the Table 3. 
 
Table 3. Bisulfite Sequencing PCR Primers 
Primer Name  Type  Sequence (5’‐3’) Amplification Condition   Size Region 
W5AR1F  Forward  AGTAATAGGATAATGATTTAATTTAATAAA  95°C‐ 10min /95°C ‐ 30s/45°C ‐ 
30s/ 63°C ‐ 30s 
393 
W5AR1R  Reverse  CAAAATACCTAAACTCACCCAATA 
W5AR2F  Forward  AGTTTTTAGATAGATTTTGTTAGGGGAGT 
95°C‐ 10min /95°C ‐ 30s/45°C ‐ 
30s/ 63°C ‐ 30s 
255 
W5AR2R  Reverse  CATAATACTAACCCCTTAAACACC 
W5APrBR2HF  Forward  GTTTAAGAGTTTTTTGTTTTTTTT  
335 
W5APrBR2HR   Reverse  AAATACCAACCCTATATCCAACTAAC 
W5aR3F#2  Forward  GAGGATTTTTGTTTGGTTTTTTTATT   95°C‐ 10min /95°C ‐ 30s/55°C ‐ 
30s/ 63°C ‐ 30s 
441 
W5AR3R  Reverse  AAACTAAATATTTTCCAACACTTTC 
W5AR4F   Forward  GTTTTGGGAATTGGTGGATTT  95°C‐ 10min /95°C ‐ 30s/45°C ‐ 
30s/ 63°C ‐ 30s 
329 
W5AR4R  Reverse  AACCCAAACTACAAAATCAACTCTC 
W5AR4F3H2   Forward  GAATTTGTTATTAATTTTTTTGTTGTTTG  95°C‐ 10min /95°C ‐ 30s/58°C ‐ 
30s/ 63°C ‐ 30s 
226 
W5AR4R3H2  Reverse  TACAAAATCAACTCTCCCCAAAA 
W5APrBR5nF  Forward  AGGGTTGTTTAGGTTTTTTTTGTTT   95°C‐ 10min /95°C ‐ 30s/45°C ‐ 
30s/ 63°C ‐ 30s 
578 
W5APrBR5nR  Reverse  AACTCCAATTTCCCTTAATCCTAAT 
W5AR6F   Forward  TTTTTTTTAGTTTGGTTGAAGAA  95°C‐ 10min /95°C ‐ 30s/55°C ‐ 
30s/ 63°C ‐ 30s 
393 
W5AR6R   Reverse  CCTAAATAATTCACTCAAAAACCC 
W5AR6H2F5  Forward  AATTAATTTTGGTTTTATTTGTTGTT   95°C‐ 10min /95°C ‐ 30s/55°C ‐ 
30s/ 63°C ‐ 30s 
96 
W5AR6H2R5  Reverse  TCAATCCCTCCTAAATAATTCACTC  
 
The primers were used to amplify their respective sodium bisulfite converted 
regions for human osteoblast and osteosarcoma SaOS-2 DNA. The amplified regions 
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were verified by size and gel purified. The purified PCR products were cloned into a 
TOPO vector and transformed into DH5α E. coli. The colonies with plasmid inserts of 
correct size were purified and sent to Eurofins MWG Operon for sequencing. The 
number of independent PCR colonies analyzed for each CpG island region is listed in 
table 4. The sequence results obtained for WNT5A Region 1 shows that all 27 CpG’s 
present in the region are unmethylated for both osteoblast and osteosarcoma SaOS-2 
DNA (Fig 7A).  The sequence data obtained for WNT5A Region 2 shows that all 39 
CpG’s present in the region are not methylated for both osteoblast and osteosarcoma 
SaOS-2 DNA (Fig 7B). The CpG’s are highlighted and numbered according to Figure 3. 
 
   Table 4. Number of independent PCR colonies analyzed for each CpG island region. 
Regions No. Of Clones analyzed 
(Osteosarcoma) 
No. Of Clones analyzed 
(Osteoblast) 
CpG Island Region 1 3 2 
CpG Island Region 2 1 1 
CpG Island Region 2H 3 1 
CpG Island Region 3 3 3 
CpG Island Region 4 4 2 
CpG Island Region 5 4 1 
CpG Island Region 6 1 3 
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Figure 7. A-G, Sequence alignment of CpG islands of computer converted (top strand) 
with bisulfite converted sequence (bottom strand). Sequence alignment between bisulfite 
converted sequence of CpG island Regions 1-6 of osteosarcoma SaOS-2 and Region 6 of 
Osteoblast  and corresponding computer converted sequence (assuming every CpG is 
methylated). 
 
 The sequencing results for WNT5A region 3 shows that the 24 CpG’s present in 
this region are unmethylated in the osteoblast DNA but are all methylated in the 
osteosarcoma SaOS-2 DNA. The 27 CpG’s for WNT5A region 4 are unmethylated in 
osteoblasts but in the osteosarcoma SaOS-2 DNA CpG’s 6 through 27 are methylated. 
The sequence data for WNT5A region 4 CpG’s 1 to 5 could not be obtained. 
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 The sequencing results for WNT5A region 5 shows that all 27 CpG’s present in 
this region are not methylated in the osteoblast DNA but CpG’s 9-27 are methylated in 
the osteosarcoma SaOS-2 DNA. Data were not available for CpG’s 1-8. The results for 
CpG island region 6 are distinct. In osteoblasts all 26 CpG’s in this region are 
unmethylated. However in the osteosarcoma SaOS-2 DNA CpG’s 1 through 14 are 
unmethylated but CpG’s 15 through 26 are methylated. The methylated CpG’s of WNT5A 
region 6 include sequences just upstream of promoter B exon 1B and sequences within 
exon 1B. Presumably, the beginning of exon 1B is the promoter B start of transcription. 
The methylation status of each CpG in all six CpG regions for osteosarcoma and 
osteoblasts are illustrated in Figure 8.  
 
 
Figure 8. Methylation status of WNT5A intron 1 CpG islands. Regions (R) 1-6. 
Methylation status of WNT5A intron 1 CpG islands. Regions (R) 1-6. The closed circles 
represent methylation and the open circles represent no methylation. The numbers 
indicate the position of each CpG within the island. 
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Reactivation of Promoter B with 5-Aza-cytidine 
 The data obtained previously in our lab showed that WNT5A promoter B 
transcripts are not expressed in osteosarcoma cells (SaOS-2). Sequence data from the 
DNA methylation analysis showed that CpG Regions 3, 4, 5 and a partial region of 6 are 
methylated and this methylation could be the reason for the decreased expression of 
WNT5A promoter B transcription. A demethylation experiment was done in order to test 
whether removal of these methyl groups would lead to an increase in WNT5A promoter B 
transcript levels. I treated osteosarcoma (SaOS-2) cells with different amounts of 5-Aza-
cytidine, a demethylating agent for 4 days. The treated cells were collected and RNA was 
isolated and used to conduct a qRT-PCR analysis of total WNT5A, promoter A and 
promoter B transcripts. 
 The data obtained from the qRT-PCR analysis of total WNT5A and promoter A in 
SaOS-2 cells treated with 0, 1, 5 and 10 µM of 5-Aza-cytidine show that in cells mock 
treated with 0 µM 5-Aza-cytidine there is no difference between the levels of the total 
WNT5A and promoter A transcript. Cells treated with 1µM of 5-Aza-cytidine show no 
significant change in the level of promoter A and total WNT5A transcripts. At 5 and 10 
µM concentrations, promoter A transcripts slightly decreased (Fig. 9, top).  
 The qRT-PCR analysis of promoter B transcripts in SaOS-2 cells treated with 0 
µM 5-Aza-cytidine there is no promoter B transcripts in osteosarcoma cells. However, in 
cells treated with 1 µM 5-Aza-cytidine there is a 120 fold increase in transcript levels of 
promoter B compared to untreated cells. In cells treated with 5 and 10 µM 5-Aza-cytidine 
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the levels of transcript from promoter B increases 65 fold and 40 fold, respectively (Fig. 
9, bottom). 
 
   
Figure 9. Reactivation of Promoter B after treatment with 5-Aza-cytidine. SaOS-2 cells 
were treated for 4 days with the indicated amounts of 5-Aza-cytidine. RNA was isolated 
and levels of total WNT5A, promoter A and promoter B specific transcripts were 
determined by qRT-PCR. Fold change is relative to untreated controls/ Error bars 
represent standard error. n=3 
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DNA Methylation Analysis after Promoter B Reactivation of WNT5A Intron 1 CpG  
 
Islands 
 
 I found that promoter B was reactivated by 5-Aza-cytidine. Next we wanted to 
determine which of the CpG islands are being most affected by the drug. It is likely that 
the regions having the most extensive demethylation have a role in regulating promoter B 
transcription. I performed bisulfite sequencing on CpG Regions 3, 4, 5 and partial region 
6 of 1 µM 5-Aza-cytidine treated SaOS-2 cells. Regions 1 and 2 were not analyzed since 
they were found to be unmethylated in osteosarcoma. The results indicate that 
demethylation is variable within the different regions, based on the analysis of multiple 
clones for each region and that Regions 3, 4 and 5 are more resistant to demethylation 
whereas, Region 6 shows greater demethylation. The methylation data were obtained for 
CpG regions 3, 4, 5 and a partial region of 6 for cells treated with 1 µM 5-Aza-cytidine. 
The results show that different clones have different demethylation patterns (Fig. 10). 
The 5 clones obtained for CpG region 3 were named G5, G7, G9, Q6 and Q10. Clone G5 
has CpG 4 demethylated. Clone G7, G9 and Q10 have CpG 24 demethylated. Clone Q6 
has CpG’s 5, 6 and 27 demethylated. The 5 clones obtained for CpG region 5 were 
named L10, L11, T6, T14, and T19. Clones L10 and T6 had demethylation in CpG 20 
and clones T14 and T19 had demethylation in CpG 22. Clone L11 showed no 
demethylation.  
 The methylation analysis for region 6 was possible for only CpG 22-26.  Among 
the three clones obtained for region 6 (R4, R11, and R16) clones R4 and R6 show CpG’s 
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23-26 demethylated while clone R11 shows no demethylation. The one clone (S15) 
obtained for CpG island region 4 CpG 6-27 shows no demethylation.  These results are 
illustrated in Figure 10. Additional clones are being analyzed. 
 
	
Figure 10. Methylation status of WNT5A intron 1 CpG islands in osteosarcoma cells 
treated with 1 µM 5-Aza-cytidine. Regions (R) 3-6. The closed circles represent 
methylation and the open circles represent no methylation. The numbers indicate the 
position of each CpG within the island.
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CHAPTER IV 
DISCUSSION 
Summary of Project and Major Findings 
 In this study, the DNA methylation status of six identified CpG islands associated 
with the WNT5A promoter B were analyzed in normal osteoblasts and the osteosarcoma 
cell line SaOS-2. My results showed that CpG island Regions 3 to 5 were completely 
methylated in the SaOS-2 DNA. Significantly, Region 6, which includes the promoter B 
start of transcription and exon 1B, was only partially methylated. Regions 1 and 2 were 
completely unmethylated. In contrast, all CpG island regions 1 to 6 were unmethylated in 
normal osteoblast cells. Treatment of SaOS-2 cells with 5-Aza-cytidine, a DNA 
demethylating agent, resulted in the reactivation of promoter B and increased promoter B 
transcripts. Bisulfite sequence analysis of the CpG islands of the 5-Aza-cytidine treated 
cells indicated that Region 6 is more prone to demethylation than the other CpG island 
regions.  These results correspond to some of the bioinformatics data for the WNT5A 
region.  In particular, in cells that normally express WNT5A (fibroblast, chondrocytes, 
and mesenchymal stem cells) there is little or no methylation of Regions 1 – 6.  However, 
in some colorectal tumor tissue there is extensive methylation within intron 1.  And, in 
adjacent normal colon mucosa tissue, Regions 3 and 4 showed some degree of 
methylation.  
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Six CpG Islands were Identified in the WNT5A Intron 1 Region 
The assumption was that sequences in intron 1 are relevant to promoter B 
expression. In order to identify these sequences we used an online computer program 
“EMBOSS CpG Plot” to screen the region for CpG islands. We identified 6 CpG islands 
and then we compared them to the CpG islands present in NCBI Epigenomics Browser 
and UCSC Genomic Browser. Figure 4 shows that our CpG islands are similar to the 
CpG islands present in the online databases. When our CpG islands are compared to the 
CpG islands in the UCSC Genome Browser, our Region 4 is not present in the browser. 
Our Region 1 contains only a part of UCSC’s CpG Region 176, which is likely to be 
associated with promoter A expression and extends across Exon 1A. Our Region 1 is 
included in WNT5A intron 1 and contains only the most 3’ region of UCSC CpG 176. 
However, the proximity of the Regions 1 and 2 to promoter A makes it more likely that 
methylation of these islands would impact promoter A function to a greater degree. In 
fact, methylation analysis of WNT5A promoter A have focused on CpG’s in exon 1A and 
of intron 1 (Ying et. al. 2008).   
 Region 6 most certainly is associated with promoter B expression. Moreover, 
using promoter B luciferase reporter constructs, 356 bp upstream of exon 1B was shown 
to be sufficient for maximal expression in SaOS-2 osteosarcoma cells (Hsu 2011). This 
result also supports the conclusion that Region 6 CpG is likely to have particular 
importance in regards to promoter B regulation. CpG island Regions 3, 4 and 5 are less 
likely to have an influence on either promoter A or B activity.  
	
	
41
Low Levels of DNA Methylation of WNT5A Intron 1 in Normal Mesenchymal Cells but 
Greater DNA Methylation in Colorectal Tumor  
 Our bioinformatics data search showed that there is only a limited number of 
studies relevant to WNT5A. There were no DNA methylation data present for 
osteosarcoma cells and only histone methylation data for osteoblast cells. Some DNA 
methylation data were present for cells that express WNT5A such as mesenchymal stem 
cells, fibroblasts and chondrocytes, which showed that the CpG islands had no or very 
little methylation. These results suggest that in normal cells that express WNT5A, these 
CpG islands are unmethylated.  Our DNA methylation results (Fig. 8) correspond to these 
observations as we found that there is no methylation of Regions 1 to 6 in normal 
osteoblast cells.  
 WNT signaling is important in colorectal cancer (Ying et al. 2008, Hibi et 
al.2009, Rawson et al. 2011), so we also looked at DNA methylation data available for 
colorectal cancer and the corresponding normal tissue.  The findings showed that in most 
cases Regions 3, 4 and 5 was methylated in normal colon and colorectal cancer. 
However, the degree of methylation in colorectal cancer was higher than in 
corresponding normal colon sample.  Also, extensive methylation in Regions 1-6 was 
present in the tumor tissue sample from patient 81 when compared to the normal (Fig. 6). 
Results suggest that there is variation in DNA methylation in Regions 1 to 6 in colorectal 
tumors but not normal cells that express WNT5A, but it appears that CpG islands 
associated with Regions 3 and 4 are often methylated. These results are consistent with 
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our findings in that we found Regions 3, 4 and 5 to be completely methylated in SaOS-2 
cells.  
 
WNT5A Intron 1 is Aberrantly Methylated in Osteosarcoma SaOS-2 Cells 
 We performed bisulfite sequencing of the intron 1 CpG Regions 1 to 6 of DNA 
from normal human osteoblast cells and osteosarcoma SaOS-2 cells.  There are no other 
published reports of similar analyses.  The results obtained for osteoblasts show that all 
CpG Regions 1-6 are unmethylated. In osteosarcoma, Regions 1 and 2 are unmethylated, 
Regions 3, 4 and 5 are methylated and Region 6 is partly methylated. 1-3 clones were 
analyzed for each region. However, for this study only one clone for osteosarcoma CpG 
Region 6 was analyzed. More clones are currently being prepared for sequencing. The 
methylated part of Region 6 contains the Exon 1B start of transcription and this 
methylation could be the reason for the repression of promoter B transcription. Regions 1 
and 2 are unmethylated and near promoter A. Possibly the high transcriptional activity of 
promoter A is somehow responsible for the lack of Region 1 and 2 methylation. The 
methylation of Regions 3, 4 and 5 could be due to other mechanisms not directly related 
to promoters A and B. These possibilities are discussed below. 
Cancer cells tend to show general global hypermethylation and gene specific 
hypomethylation (Shen et al. 2013).  WNT5A is one gene that is subject to epigenetic 
modification by DNA methylation (see Introduction).  Our data confirm this general 
conclusion as we found that WNT5A is methylated at specific CpG islands in 
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osteosarcoma SaOS-2. We do not know if this pattern of methylation is unique to SaOS-2 
cells or more common to all osteosarcoma tumor cells.  This is currently being explored 
in our lab.  From the bioinformatics data it appears that certain CpG islands in WNT5A 
are prone to methylation, particularly Regions 3 and 4.  It has been suggested that 
aberrant methylation in cancer could be a result of stochastic effects, where DNA 
methylation takes place randomly in retrotransposon sequences such as LINE (Long 
Interspersed Elements) and SINE (Short Interspersed Elements), which are present 
throughout the human genome (Estécio et al. 2012 and 2010 ).  Insulator proteins such as 
the CTCF and USF 1/2 also influence patterns of DNA methylation (Van Roon et al. 
2011).  Also DNA methylation could be affected by other sequences such as the 
proximity of active promoters. CpG Regions 1 and 2 are located near promoter A, which 
is highly active in osteosarcoma SaOS-2 cell line. The active promoter A could have on 
effect on Regions 1 and 2, keeping them free of methylation. This would include 
particular histone modifications associated with active transcription including H3K4me3 
and H3K9ac and the RNA polymerase transcription itself.   
CpG Regions 3, 4 and 5 are likely not involved in promoter A or B 
regulation/expression due to their locations within intron 1. The aberrant methylation of 
these regions could be due to the presence of LINE and SINE sequences in the regions. 
However, examination of the data available in the UCSC Genome Browser for LINE and 
SINE repeats shows that there are no such repeats in the regions.  Another reason for the 
aberrant methylation of these regions could be due to insulator proteins, e.g. CTCF and 
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USF 1/2 . An ENCODE search for insulator proteins CTCF and USF 1/2 in osteoblasts 
showed that intron 1 includes binding sites for the insulator protein CTCF (Fig. 11). 
Possibly the type of sequence of Regions 3 and 4, plus the presence of insulators lead to 
aberrant methylation during transformation. 
 
 
 
Figure 11. Insulator protein CTCFs are present in the WNT5A intron 1 region. Screen shot 
from WNT5A genomic region of ENCODE search for CTCF.  
 
 CpG region 6 is associated directly with promoter B and it is only partially 
methylated. The reason for this partial methylation could be due to histone modification 
associated with active transcription e.g. H3K4me3 and H3K9ac. A NCBI epigenomics 
search for histone modifications in osteoblast samples showed that there are histone 
modifications H3K4me1 and H3K36me3, which are related to transcriptional activation 
near Region 6. Also, CTCF insulator protein binding site is present near region 6 (Fig. 
12). The histone modifications, insulator proteins combined with distinct sequences of 
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the region may contribute to a distinct pattern of DNA methylation during 
transformation.     
 
 
Figure 12. H3K4me1 and H3K36me3 and CTCF insulator protein binding sites in 
WNT5A Intron 1 region.   
 
Promoter B is Activated by 5-Aza-cytidine and Region 6 is Prone to Demethylation 
Promoter B is inactive or active at a low level in SaOS-2 cells.  In comparison, 
transcripts from promoter B are highly expressed in normal osteoblast cells.  My results 
indicate that promoter B inactivity in SaOS-2 cells is associated with DNA methylation. 
To test for causality, we treated the SaOS-2 cells with 5- Aza-cytidine that inhibits DNA 
methyl transferases (DNMT’s), enzymes responsible for the addition of the methyl 
groups and causes hypomethylation. 
My hypothesis is that 5-Aza-cytidine should increase promoter B transcript levels 
and decrease methylation of the promoter B associated CpG islands.  Indeed, we found 
that SaOS-2 cells that had been treated with different concentrations of 5-Aza-cytidine 
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increased promoter B transcript levels, there was a slight decrease of promoter A 
transcript levels.  
 When a concentration of 1 μM 5-Aza-cytidine was used promoter B transcripts 
increased 120 fold. Treatment with 5 μM and 10 μM resulted in lower amounts of 
promoter B transcripts when compared to 1 μM. This might be because 5-Aza-cytidine 
causes global DNA methylation, other genes may be activated that are affecting promoter 
B transcription. Also, 5-Aza-cytidine increases cytotoxicity and can cause cell death.  
Bisulfite sequencing analysis of the CpG islands indicated that Regions 3, 4 and 5 
were resistant to demethylation.  Only a few demethylation changes were detected.  
However, of the clones that have been analyzed for Region 6, two showed more 
extensive demethylation. Of the 5 CpG’s, 4 were demethylated in the two clones. This 
result indicates that Region 6 is more prone to de methylation.  Currently more Region 6 
clones are being analyzed. 
Region 6 most certainly associated with promoter B expression. As previously 
discussed, Region 6 is likely to have a distinct chromatin state in comparison to Regions 
3, 4 and 5, due to its inclusion of promoter B transcription start site and Exon 1 B 
sequences. This may also explain why this region is more prone to demethylation. The 
finding that Region 6 is only partially methylated suggest that it is also protected from 
methylation. It will be interesting to determine the types of histone modifications 
associated with the Region 6 in comparison to Regions 3, 4 and 5. 
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Future Plans 
 
To further study the role of DNA methylation in WNT5A Promoter B expression 
in osteosarcoma, DNA methylation profiles in the CpG islands of other osteosarcoma cell 
lines such as the U2OS cell line should be determined. We should also quantify the levels 
of promoter A and promoter B transcripts in these cell lines. Another experiment would 
be to obtain patient samples of osteosarcoma and adjacent normal tissues and measure the 
promoter A and promoter B transcript levels and analyze the amount of DNA 
methylation present in the CpG islands. Together these studies will answer the questions: 
Is there a specific, defined pattern of DNA methylation associated with osteosarcoma 
tumors or is DNA methylation variable across the WNT5A intron 1 region? And, is 
promoter B transcription always reduced in osteosarcoma tumors? Additional studies will 
need to focus on the functional distinction between WNT5A protein isoforms A and B, 
derived from the unique transcripts of promoter A and 
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